non contrast enhanced MRI
Diagnostic Test6 monthly non contrast enhance MRI
NCT Number: NCT06658782
Aim: To use magnetic resonance imaging (MRI) scans without contrast to help improve diagnosis of liver cancer in people who are at increased risk of developing liver cancer.
Background: People with any condition that affects the liver over a long period of time can develop cirrhosis. Conditions and risk factors that can lead to cirrhosis include alcohol excess, liver steatosis (lipid or fat accumulation in the liver) and infection with the viruses hepatitis B and C. One of the concerns about people with cirrhosis is that they are at increased risk of developing liver cancer. People with cirrhosis are recommended to have an ultrasound scan (USS) every 6 months (surveillance for liver cancer) so that if a cancer develops, it is diagnosed at an early stage when it can be cured. However, ultrasound can miss cancers even in people having scans every 6 months. Furthermore, the risk of cancer is not alike among people with cirrhosis. For example, people with more advanced cirrhosis and those with cirrhosis from hepatitis B are at higher risk. It is therefore possible that better tests than ultrasound are needed for people with cirrhosis who are at particularly high risk of developing cancer.
Computed tomography (CT) and Magnetic Resonance Imaging (MRI) scans with dye injection (contrast) are used for liver cancer diagnosis. However, they cannot be done every 6 months because of costs, capacity and toxicity from high CT radiation doses, and MRI contrast build-up in the brain with repeated MRI contrast injections. MRI scans without contrast are not toxic, could be done in 20 minutes and are cheaper, so could be done every 6 months. In the experience of the study investigators, MRI without contrast may raise suspicion of liver cancer in cases missed by ultrasound, so it could be used for surveillance instead of ultrasound. This study aims to find out if it is feasible to use a quick MRI (20 minutes) without contrast as surveillance for liver cancer in people at high risk of liver cancer due to liver cirrhosis and to compare this MRI with ultrasound.
Design and Methods: The investigators will recruit 300 people at higher risk of developing liver cancer because of cirrhosis. Study participants will have an ultrasound scan every 6 months as they would in their standard clinical care and an additional 6 monthly non-contrast MRI scan for 30 months (6 visits). If the ultrasound or non-contrast MRI raises concern for a possible liver cancer, an MRI scan with contrast (with dye injection) will be done for definitive diagnosis. All participants will have an MRI with contrast at the end of 30 months (M30) to ensure that no cancers were missed. Participants will be asked to complete questionnaires to measure quality of life, anxiety, and their experience of MRI and ultrasound scans and data will be collected from their medical notes. The number of liver cancers detected by ultrasound will be compared to the number detected by the non-contrast MRI scans.
Interested in participating?
Request Info18 year and older
All sexes
Observational
Oxford University Hospitals NHS Foundation Trudt, Oxford, Oxon, United Kingdom
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
6 monthly non contrast enhance MRI
Time frame: from enrolment to 30 months
True positive tests for HCC per round of surveillance False positive tests for HCC per round of surveillance Positive predictive value for HCC per round of surveillance True negative tests for HCC over the 30 months of surveillance False negative tests for HCC over the 30 months of surveillance Sensitivity and specificity of nceMRI and USS for HCC over 30 months of surveillance
Time frame: from enrolment to 30 months
Numbers of HCC detected by nceMRI and USS at a very early, early, intermediate or advanced stage as defined by the Barcelona Clinic Liver Cancer staging system.
The number and size of HCC tumours per participant with HCC The number of new indeterminate lesions identified at each surveillance round
Time frame: from enrolment to 30 months
Proportion of participants diagnosed with HCC who go on to receive treatment with curative intent
Time frame: from enrolment to 30 months
Results of the EQ-5D-5L questionnaire and Hospital Anxiety and Depression Scale questionnaire
Time frame: baseline, and month 24
Results of participant experience questionnaire
Time frame: from enrolment to 30 months
We will count how many appointments for HCC surveillance are unused due to appointments that are missed by participants or cancelled buy the health care provider, or due to participants being lost to follow-up or participants where HCC surveillance is no longer indicated.
Time frame: month 30
Sensitivity and specificity of multivariable models for the diagnosis of HCC
Time frame: from baseline to months 30
Quantitative variables extracted from MRI data; T1 (ms), R2* (ms), PDFF (%), ADC (mm2/s)
Time frame: Up to 10 years after the last study MRI scan is performed
A composite end point including the outcomes of: all cause mortality, liver related mortality, liver decompensation (ascites, hepatic encephalopathy, variceal bleeding), hepatocellular cancer, non primary liver cancer, liver transplantation.
Contact information is provided by the study sponsor or research team.
University of Oxford
Other
Acronym: AMULET
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05832229
Alcohol-Induced Disorders, Alcohol-Related Disorders
La Jolla, California, United States
View Trial DetailsNCT05095714
Adenocarcinoma, Carcinoma
Bondy, France
View Trial DetailsNCT06007846
Adenocarcinoma, Carcinoma
Fairfax, Virginia, United States
View Trial DetailsNCT05201404
Adenocarcinoma, Carcinoma
Dallas, Texas, United States
View Trial Details